Adverse, drug reactions interactions between drugs

Fig. 1 The multigenic and multifactorial nature of idiosyncratic adverse drug reactions. The occurrence of an idiosyncratic reactions is dependent on the interaction between multiple genes and environmental factors...

Other patients taking warfarin have been found to have INRs of 5.6 five days after starting clarithromycin, of 90.3 five days after completing a 10-day course of clarithromycin, of 17 five days after finishing a 14-day course of clarithromycin, and of 7.3 within 12 days of starting clarithromycin. None of these patients had bleeding complications. In a brief report in 2004, the Adverse Drug Reactions Advisory Committee of Australia state that they had received 6 reports of interactions between clarithromycin and warfarin (median INR of 7.6), two of which were symptomatic. ... 

In contrast, one report describes 2 patients stabilised on warfarin who had marked rises in their INRs (to 6.2 and 7.3), and another patient recently started on warfarin who had a more modest rise (to 4.2) within 1 to 5 days of starting moxifloxacin. All these patients had recently been receiving other antibacterials, which complicates interpretation. For the period October 2000 to January 2004, Health Canada h received 12 reports of suspected coagulation disorders associated with moxifloxacin and warfarin, 11 of which were considered serious. Similarly, in February 2006, the Australia Adverse Drug Reactions Advisory Committee stated they had received one report of a suspected interaction between warfarin and moxifloxacin. In this patient the DSTR rose from around 2 to greater than 10, four days after starting moxifloxacin. ... 

Health Canada had received 6 reports of suspected coagulation disorders associated with norfloxacin and warfarin, 4 of which were considered serious. Similarly, in February 2006, the Australia Adverse Drug Reactions Advisory Committee stated they had received 11 reports of a suspected interaction between warfarin and norfloxacin. ... 

Dose adjustment for combination therapy with saquinavir For serious toxicities that may be associated with saquinavir mesylate, the drug should be interrupted. Saquinavir mesylate at doses less than 1,000 mg with ritonavir 100 mg twice daily are not recommended since lower doses have not shown antiviral activity. For recipients of combination therapy with saquinavir mesylate and ritonavir, dose adjustments may be necessary. These adjustments should be based on the known toxicity profile of the individual agent and the pharmacokinetic interaction between saquinavir and the coadministered drug. Health care providers should refer the complete monographs for these drugs for comprehensive dose adjustment recommendations and drug-associated adverse reactions of nucleoside analogues. 

Adverse effects Hi receptor blockers have a low specificity, that is, they interact not only with histamine receptors but also with muscarinic cholinergic receptors, a-adrenergic receptors, and serotonin receptors (see Figure 40.6). The extent of interaction with these receptors and, as a result, the nature of the side effects, vary with the structure of the drug. Some side effects may be undesirable, and others may have therapeutic value. Furthermore, the incidence and severity of adverse reactions varies between individual subjects. 

The main systems affected by adverse effects of the quinolones are the skin, liver, and nervous system. The best-known adverse effect is phototoxicity, the risk of which varies markedly among the quinolones lomefloxacin and sparfloxacin carry a particularly high risk. The development of phototoxicity is based on an interaction between hght and the drug. Neurotoxicity also occurs, with marked variation of incidence between the various compounds. Hypersensitivity reactions to quinolones are rare, and include anaphylactic shock and anaphylactoid reactions. Organ-specific reactions attributed to hypersensitivity involve the liver and kidneys. If hypersensitivity reactions occur, switching from one qui-nolone compound to another is probably not advisable, since there is cross-reactivity. 

The Pharmacokinetics section of each chapter covers absorption, tissue distribution, elimination, and body fluid concentrations. Such pharmacokinetic information is usually not included in other sources and may be useful in forensic investigations or in the clinical setting regarding use of the product in patients with renal or hepatic insufficiency. A section on Adverse Effects and Toxicity follows and includes detailed information on case reports of adverse reactions to the herb. The Interactions section includes discussions of interactions between the supplement and drugs or foods. The Reproduction section follows and is generally limited because of lack of information. Each chapter ends with a discussion of Regulatory Status of the product. The amount of information included in each of these sections varies according to availability. 

---